Notably, the XPO1 inhibitor selinexor can be used for the treatment of multiple myeloma and DLBCL, and the FDA has approved selinexor for adult patients with r/r DLBCL 35-37. This evidence concerns the gene XPO1 and diffuse large B-cell lymphoma.